- Trial phase
- Phase 2
- Time to market
- Uncertain. Phase 2 is complete; GSK will need to design and execute Phase 3 trials before any regulatory filing, which typically takes 3-5+ years for a novel MASH therapy.
- Why 3/10
- No hard, dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled for efimosfermin within the next ~12 months. The Phase 2 trial (NCT04880031) is complete, and while Breakthrough/PRIME designations are positive signals, there is no registered Phase 3 trial or known regulatory submission date. Additionally, efimosfermin is a tiny pipeline asset inside a ~$106B mega-cap pharma, limiting any single-drug impact on GSK shares.
Monitor for GSK-initiated Phase 3 trial registration and for formal Phase 2 data disclosure at a hepatology conference (e.g., AASLD/EASL). Neither event has a confirmed date, so efimosfermin is not a near-term trading catalyst for GSK. The drug is a small pipeline component of a diversified pharma giant and carries limited stock-moving potential even on positive news.
Price Chart
Executive Summary
Efimosfermin (development code BOS-580) is GSK's investigational therapy for MASH (formerly NASH), a progressive liver disease with limited treatment options. A 231-patient Phase 2 trial completed in October 2025, and the data earned FDA Breakthrough Therapy and EMA PRIME designations in early 2026 based on improvements in liver fibrosis and MASH resolution. However, Phase 2 results have not been formally published, no Phase 3 trial has been registered, and the drug represents a negligible portion of GSK's ~$106B market cap. This is a promising but very early-stage pipeline asset in a historically difficult therapeutic area, positive de-risking, but not a stock-moving catalyst anytime soon.
How It Works
Efimosfermin (BOS-580) is an investigational injectable therapy for MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH), a serious liver disease caused by fat buildup that leads to inflammation and scarring. It works by targeting metabolic pathways involved in liver fibrosis (scarring) and inflammation. Exactly which biological pathway it modulates (likely an FGF21-analog mechanism based on the drug class and indication) has not been disclosed publicly by GSK in available filings.
Trial Status
A 231-patient Phase 2 trial (NCT04880031) in obese subjects at risk for, or with biopsy-confirmed, NASH completed primary data collection in October 2025. Trial results have not been publicly posted yet (hasResults=false on ClinicalTrials.gov), but the data was sufficiently positive to earn FDA Breakthrough Therapy designation and EMA PRIME designation in early 2026 for the treatment of MASH. These designations are based on Phase II data showing improvement in liver fibrosis and MASH resolution.
The Two-Sided Case
Upcoming Catalysts
- Full Phase 2 data disclosure at a medical conference (date not announced)
- Initiation of Phase 3 trial design/start
- Any regulatory meeting outcomes regarding Phase 3 pathway
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report